Axogen plans to process only human nerve tissue for Avance and other products at the new facility, which is being built to cGMP standards, and is intended to support a future Biologics License Application (BLA) for Avance Nerve Graft to the FDA . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Tissue Growth: Axogen’s Biologic Transition Leads to Expansion appeared first on GEN – Genetic Engineering and Biotechnology News.
